You may be trying to access this site from a secured browser on the server. Please enable scripts and reload this page.
Turn on more accessible mode
Turn off more accessible mode
Skip Ribbon Commands
Skip to main content
Turn off Animations
Turn on Animations
CTDetailNew
It looks like your browser does not have JavaScript enabled. Please turn on JavaScript and try again.
Appointment
Find a Condition or Treatment
Find a Doctor
Menu
MAIN
Back to Home
About Us
Corporate Profile
Academic Clinical Programme (EYE ACP)
Newsroom
Calendar of Events
Contact Us
Patient Care
Conditions & Treatments
Specialties & Services
Your Clinic Visit
Day Surgery
Getting to SNEC
E-Services
Research & Innovation
About SERI
Research Groups & Platforms
Research Impact
Clinical Trials
Key Programmes
SingHealth Research
Education & Training
Overview
Residency
Fellowships
Other Programmes
SingHealth Academy
Careers
Why Choose Us
Career Choices
Job Opportunities
Sponsorships & Scholarships
Contact us
Giving
Why Give
Get Involved
Your Gift At Work
Be Informed
Make A Gift
Conditions & Treatments
Back to Home
Eye Conditions & Treatments
Common Eye Symptoms
Eye Conditions Brochures
Post-operative Care & Advice Leaflets
Patient Education Videos
Find a Doctor
Find a Medicine
Health Xchange
Specialties & Services
Back to Home
Clinical Subspecialties
Allied Health Services
Nursing
Your Clinic Visit
Back to Home
Clinic Locations
Patient & Visitor Policy
Registering at the Specialist Clinic
Patient Classification
Outpatient Consultation Charges
Financial Assistance
Digital Medical Certificates
Collecting Your Medication
Bill Payment Options
Information for Travellers
Public Wifi
Lasting Power of Attorney
Day Surgery
Getting to SNEC
Back to Home
Getting to SNEC
Car Park Information
Shuttle Service
Wheelchair Shuttle Service
Amenities
SNEC Branches & Affiliated Clinics
Contact Us
E-Services
Back to Home
Make/Change/Cancel Appointment
Pay Online
Request for Final Bill
Request for Medical Report
Medication Delivery Service
Health Buddy App
Online Eye Consultation
Feedback & Enquiry
Optical Shop Partners
EySEE – Self Check Eye Test
Home
to skip to the main content on a page
to skip to the main content on a page
About Us
Back to Home
Corporate Profile
Academic Clinical Programme (EYE ACP)
Newsroom
News Articles
Press Releases
Publications
SNEC Magazine (SINGVISION)
EyeSight
Calendar of Events
Contact Us
Check Fake News
Patient Care
Back to Home
Conditions & Treatments
Eye Conditions & Treatments
Common Eye Symptoms
Eye Conditions Brochures
Post-operative Care & Advice Leaflets
Patient Education Videos
Find a Doctor
Find a Medicine
Health Xchange
Specialties & Services
Clinical Subspecialties
Allied Health Services
Nursing
Your Clinic Visit
Clinic Locations
Patient & Visitor Policy
Registering at the Specialist Clinic
Patient Classification
Outpatient Consultation Charges
Financial Assistance
Digital Medical Certificates
Collecting Your Medication
Bill Payment Options
Information for Travellers
Public Wifi
Lasting Power of Attorney
Day Surgery
Getting to SNEC
Getting to SNEC
Car Park Information
Shuttle Service
Wheelchair Shuttle Service
Amenities
SNEC Branches & Affiliated Clinics
Contact Us
E-Services
Make/Change/Cancel Appointment
Pay Online
Request for Final Bill
Request for Medical Report
Medication Delivery Service
Health Buddy App
Online Eye Consultation
Feedback & Enquiry
Optical Shop Partners
EySEE – Self Check Eye Test
Research & Innovation
Back to Home
About SERI
Research Groups & Platforms
Research Impact
Clinical Trials
Key Programmes
SingHealth Research
Education & Training
Back to Home
Overview
Residency
Fellowships
Local Fellowship
Overseas Fellowship
Other Programmes
Undergraduate Programmes
Observerships
Continuing Medical Education (CME)
Ophthalmic Nursing, Paramedical & Technician Training Courses
SingHealth Academy
Careers
Back to Home
Why Choose Us
Career Choices
Job Opportunities
Sponsorships & Scholarships
Contact us
Giving
Back to Home
Why Give
Singapore's Eye Health
Finding A Cure
Advancing Medical Education
Helping Our Patients
Reaching Out to the Community
Further Donor Impact
Get Involved
Make A Gift
Leave A Legacy
Become A Corporate Donor
Establish A Professorship
Create A Name Fund
Honour A Healthcare Hero
THE EYE BALL
Charity Golf Tournament
Your Gift At Work
Meet Grateful Patients
Meet Donors Like You
Meet Our Researchers
Meet Our Educators
Be Informed
Latest News
What's Happening
About VisionSave
Our Publications
Visionary Award
Inspirational Patient Award
Make A Gift
Home
>
Patient Care
>
Conditions and Treatment
>
Lutetium-177 PSMA (LuPSMA) radionuclide therapy
Facebook
WhatsApp
Email Us
share
Font Resize
A-
A
A+
Print
Lutetium-177 PSMA (LuPSMA) radionuclide therapy
Lutetium-177 PSMA (LuPSMA) radionuclide therapy - What it is
Lutetium-177 PSMA (LuPSMA) radionuclide therapy - Symptoms
Lutetium-177 PSMA radionuclide therapy is used for treating patients with advanced prostate cancer. Prostate cancers, in particular those that have spread to other sites of the body or become resistant to hormonal therapies, express a unique substance on their cell surface called prostate specific membrane antigen (PSMA). LuPSMA radionuclide therapy involves using a radioactive molecule (Lutetium-177) and PSMA substance that specifically attaches to cells with high PSMA expression. This radioactive molecule is taken up into prostate cancer cells, or wherever the disease has spread and enables delivery of high doses of targeted radiation to sites of prostate cancer whilst sparing most normal tissues. This is called radionuclide therapy as it uses radiation to kill prostate cancer cells.
Why do I need this treatment?
The use of LuPSMA therapy is largely for patients who have progressive metastatic hormone-resistant prostate cancer. You may be referred for this treatment if there is progression of your condition despite having undergone conventional therapy (such as hormonal treatment and chemotherapy). Hormonal treatment and other systemic therapies may control the disease for some periods of time, however many patients eventually suffer a relapse of the disease.
The benefits of this targeted radionuclide therapy may include shrinkage of tumours, a reduction in blood Prostate Specific Antigen (PSA) level, improvement in symptoms such as pain and a general improvement in well-being.
Lutetium-177 PSMA (LuPSMA) radionuclide therapy - How to prevent?
Lutetium-177 PSMA (LuPSMA) radionuclide therapy - Causes and Risk Factors
Lutetium-177 PSMA (LuPSMA) radionuclide therapy - Diagnosis
Lutetium-177 PSMA (LuPSMA) radionuclide therapy - Treatments
What does it involve?
LuPSMA treatment is an outpatient treatment. It will be administered via an intravenous line into the veins of your arms.
You will receive up to 4 -6 cycles of LuPSMA treatment at 6-8 week intervals.
What precautions must I take for the treatment?
Standard supportive drugs, hormonal therapy, biosphosphonate therapy or palliative radiotherapy while on LuPSMA therapy is permissible as clinically indicated. Concurrent chemotherapy while receiving LuPSMA therapy is currently not permitted.
It is important to tell your doctor about any treatments or medications you may be taking, including over-the-counter medications, vitamins or herbal remedies, acupuncture or other alternative treatments, and any changes to these medications during your LuPSMA therapy.
What are the risks of the treatment?
Possible short term side effects (within weeks to months of treatment):
1. Nausea (very common: more than 1 in 10)
This is usually mild and, if needed, can be treated with anti-nausea medication.
2. Injury to salivary or lacrimal (tear) glands (very common: more than 1 in 10)
These gland cells have PSMA-receptors, which LuPSMA will attach to. Therefore, the glands will receive radiation. This may result in inflammation (swelling) of the glands which may lead to pain or decreased production of saliva and/or tears. This will most likely be temporary and resolve with time. Permanent injury (e.g. reduced production of saliva or tears) is possible but is usually mild and can be alleviated with artificial saliva and tear drops.
3. Increased pain or pressure effects from swelling due to radiation damage at sites of tumours (common: between 1 in 10 and 1 in 100)
This is usually temporary but may require increase in painkiller requirements.
4. Flu-like symptoms (common: between 1 in 10 and 1 in 100)
As tumours die, this can result in flu-like symptoms including low grade fevers and fatigue.
5. Bleeding or infection as a result of reduction in blood count (uncommon: likelihood of less than 1 in 100 to 1 in 1000)
The extent of blood count reduction may be influenced by prior therapies (e.g. chemotherapy). If you have very extensive bone metastases, this may also increase the likelihood of reduced blood count. Mild reduction in blood count that can be measured through blood tests without any resulting symptoms may be more common (between 1 in 10 and 1 in 100).
6. Kidney failure (uncommon: likelihood of less than 1 in 100 to 1 in 1000)
Reduced glomerular filtration rate of the kidneys has been observed following LuPSMA therapy, however this usually does not result in kidney dysfunction clinically for most patients.
Possible longer-term side effects
Longer-term side effects may include risk of developing secondary malignancies. The precise increase in risk is not known but thought to be very small (less than 1 in 100) and will depend somewhat on the radiation doses absorbed during the treatment. However, the risk of serious sequelae is relatively rare and typically involves blood disorders that may develop several years after treatment.
What can I expect after the treatment?
After each treatment, a whole body 2-dimensional scan and a more detailed 3-dimensional scan will be performed to see where the radiation has gone to. This scan will take approximately 45-60 minutes to complete. Most patients will feel well and be allowed to go home on the day of treatment.
However, you will be mildly radioactive for a few days and there may be some restrictions on close personal contact including with pregnant women or children.
Your blood will be taken and tested (full blood count, urea and electrolytes, liver function tests, PSA) at 14 and 28 days after the treatment.
Further LuPSMA treatments can be considered for patients who responded to initial cycles of LuPSMA but subsequently progressed, provided they continued to meet the eligibility criteria for treatment.
Lutetium-177 PSMA (LuPSMA) radionuclide therapy - Preparing for surgery
Lutetium-177 PSMA (LuPSMA) radionuclide therapy - Post-surgery care
Lutetium-177 PSMA (LuPSMA) radionuclide therapy - Other Information
Symptoms
Article contributed by
Nuclear Medicine and Molecular Imaging
,
Singapore General Hospital
The information provided is not intended as medical advice.
Terms of use
. Information provided by
Our Breast Team
Filter:
By designation or sub-specialty
By Designation:
By Sub-Specialty:
TOP
[]
Related Conditions
Related Medications
Healthy Living Tips
by
View more
Discover articles,videos, and guides afrom Singhealth's resources across the web. These information are collated, making healthy living much easier for everyone.
Braces How to Take Care
Festive Feasting How to Avoid Overeating
Post-Stroke Exercises (Lower Limb Strength Training)
Post-Stroke Exercises (Upper Limb Strength Training)
×
SUBSCRIBE VIA EMAIL
Subscribe to our mailing list to get the updates to your email inbox...
Find a Doctor
Conditions & Treatments
Home
Appointment
E-Services